Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy

Chemotherapy

Volumn 58, Issue 6, 2013, Pages 426-434

  Oh, Sung Yong ^a   Kwon, Hyuk Chan ^a   Kim, Sung Hyun ^a   Lee, Suee ^a   Lee, Ji Hyun ^a   Graves, Christian A ^b   Camphausen, Kevin ^b   Kim, Hyo Jin ^a  

^a Dong A University College of Medicine   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

FOLFOX; Gastric carcinoma; Insulin like growth factor 1; Vascular endothelial growth factor

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; SOMATOMEDIN C; VASCULOTROPIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; STOMACH ADENOCARCINOMA; SURVIVAL TIME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROURACIL; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LEUCOVORIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84871881545     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000345918     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, Lee JS: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 2011; 43: 1-11.
3. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
4. Pasini F, Fraccon AP, G De Mazoni G: The role of chemotherapy in metastatic gastric cancer. Anticancer Res 2011; 31: 3543-3554.
5. Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, Kim HJ: A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol 2007; 46: 336-341.
6. Kim YS, Hong J, Sym SJ, Park SH, Park J, Cho EK, Lee JH, Shin DB: Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy asa salvage treatment in advanced gastric cancer. Cancer Res Treat 2010; 42: 24-29.
7. Xiang XJ, Zhang L, Qiu F, Yu F, Zhan ZY, Feng M, Yan J, Zhao JG, Xiong JP: A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer. Chemotherapy 2012; 58: 1-7.
8. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
9. Eroglu A: Serum levels of vascular endothelial growth factor in gastric cancer patients. J Surg Oncol 2011; 104: 222.
10. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T: Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol 1997;15: 826-832.
11. Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, Xu N: Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep 2012; 39: 9473-9484.
12. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M: Prognostic value of vascular endothelial growth factorexpression in gastric carcinoma. Cancer 1996; 77: 858-863.
13. Chen J, Li T, Wu Y, He L, Zhang L, Shi T, Yi Z, Liu M, Pang X: Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2011; 137: 1799-1812.
14. Poon RT, Fan ST, Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001; 19: 1207-1225.
15. Vidal O, Metges JP, Elizalde I, Valentini M, Volant A, Molina R, Castells A, Pera M: High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg 2009; 96: 1443-1451.
16. Karayiannakis AJ, Syrigos KN, Zbar A, Baibas N, Polychronidis A, Simopoulos C, Karatzas G: Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 2002; 131: 548-555.
17. Kitamura M,Toi M,Arai K,Iwasaki Y,Suzuki H,Matsuo K. Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients. Oncol Rep 1998; 5: 1419-1424.
18. Seo HY, Park JM, Park KH, Kim SJ, Oh SC, Kim BS, Kim YH, Kim JS: Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients.Jpn J Clin Oncol 2010; 40: 1147-1153.
19. Le Roith D: Seminars in medicine of the Beth Israel Deaconess Medical Center: insulinlike growth factors. N Engl J Med 1997; 336: 633-640.
20. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights Endocr Rev 2007; 28:20-47.
21. Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159-169.
22. LeRoith D, Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127-137.
23. Lee DY, Kim SJ, Lee YC: Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 1999; 14: 401-404.
24. Han JY, Choi BG, Choi JY, Lee S Y, Ju SY.The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer 2006; 54:227-234.
25. Han JY, Choi BG, Choi JY, Lee SY, Ju SY: The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer 2006; 54: 227-234.
26. Lee DY, Yang DH, Kang CW, Kim SJ, Joo CU, Cho SC, Kim JS: Serum insulin-like growth factors (IGFs) and IGF binding protein (IGFBP)-3 in patients with gastric cancer: IGFBP-3 protease activity induced by surgery. J Korean Med Sci 1997; 12: 32-39.
27. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ: Prognosticvalue of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007; 18: 504-509.
28. Seo BG, Kwon HCOh SY, Lee S, Kim SG, Kim SH, Han H, Kim HJ: Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncol Rep 2009; 22: 127-136.
29. Wu Y, Yakar S, Zhao L, Hennighausen L, Le- Roith D:Circulating insulin-like growth factor- I levels regulate colon cancer growth and metastasis. Cancer Res 2002; 62: 1030-1035.
30. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM: Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 1998; 58: 4008-4014.
31. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, Bucana CD, Evans DB, Semenza GL, Ellis LM: Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin- like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 2003; 163: 1001-1011.
32. Li H, Adachi Y, Yamamoto H, Min Y, Ohashi H, Ii M, Arimura Y, Endo T, Lee CT, Carbone DP, Imai K, Shinomura Y: Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer 2011; 117: 3135-3147.
33. Shitara K, Ito S, Misawa K, Ito Y Ito H, Hosono S, Watanabe M, Tajima K, Tanaka H, Muro K, Matsuo K: Genetic polymorphism of IGF-I predicts recurrence in patients with gastric cancer who have undergone curative gastrectomy. Ann Oncol 2012;23: 659-664.
34. Izycki T, Chyczewska E, Naumnik W, Talalaj J, Panek B, Ossolinska M: Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy. Exp Oncol 2004; 26: 316-319.